Matinas Biopharma (MTNB) Competitors $2.36 +0.71 (+43.03%) Closing price 04:00 PM EasternExtended Trading$2.42 +0.06 (+2.71%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MTNB vs. CALC, ENLV, SNYR, PLUR, STTK, XLO, PEPG, EQ, ALXO, and AKTXShould you be buying Matinas Biopharma stock or one of its competitors? The main competitors of Matinas Biopharma include CalciMedica (CALC), Enlivex Therapeutics (ENLV), Synergy CHC (SNYR), Pluri (PLUR), Shattuck Labs (STTK), Xilio Therapeutics (XLO), PepGen (PEPG), Equillium (EQ), ALX Oncology (ALXO), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical products" industry. Matinas Biopharma vs. Its Competitors CalciMedica Enlivex Therapeutics Synergy CHC Pluri Shattuck Labs Xilio Therapeutics PepGen Equillium ALX Oncology Akari Therapeutics CalciMedica (NASDAQ:CALC) and Matinas Biopharma (NYSE:MTNB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability. Does the media favor CALC or MTNB? In the previous week, CalciMedica had 7 more articles in the media than Matinas Biopharma. MarketBeat recorded 8 mentions for CalciMedica and 1 mentions for Matinas Biopharma. Matinas Biopharma's average media sentiment score of 1.00 beat CalciMedica's score of 0.36 indicating that Matinas Biopharma is being referred to more favorably in the news media. Company Overall Sentiment CalciMedica Neutral Matinas Biopharma Positive Which has preferable earnings and valuation, CALC or MTNB? CalciMedica is trading at a lower price-to-earnings ratio than Matinas Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalciMedicaN/AN/A-$13.70M-$1.60-1.82Matinas BiopharmaN/AN/A-$22.94M-$3.89-0.61 Do analysts rate CALC or MTNB? CalciMedica currently has a consensus target price of $16.00, indicating a potential upside of 449.83%. Given CalciMedica's stronger consensus rating and higher probable upside, equities analysts plainly believe CalciMedica is more favorable than Matinas Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CalciMedica 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Matinas Biopharma 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility and risk, CALC or MTNB? CalciMedica has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, Matinas Biopharma has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Is CALC or MTNB more profitable? Matinas Biopharma's return on equity of -123.06% beat CalciMedica's return on equity.Company Net Margins Return on Equity Return on Assets CalciMedicaN/A -206.51% -103.81% Matinas Biopharma N/A -123.06%-94.28% Do institutionals & insiders hold more shares of CALC or MTNB? 11.8% of Matinas Biopharma shares are held by institutional investors. 41.6% of CalciMedica shares are held by company insiders. Comparatively, 4.6% of Matinas Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryCalciMedica beats Matinas Biopharma on 8 of the 13 factors compared between the two stocks. Get Matinas Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTNB vs. The Competition Export to ExcelMetricMatinas BiopharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$8.39M$811.04M$5.68B$20.89BDividend YieldN/A4.84%4.59%3.57%P/E Ratio-0.491.1930.6827.95Price / SalesN/A26.14463.8054.72Price / CashN/A19.5638.2123.95Price / Book0.536.588.995.23Net Income-$22.94M-$4.98M$3.25B$994.11M7 Day Performance108.85%3.14%4.76%1.78%1 Month Performance138.29%2.50%6.72%2.03%1 Year PerformanceN/A17.33%30.51%12.80% Matinas Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTNBMatinas Biopharma1.5306 of 5 stars$2.36+43.0%N/AN/A$8.39MN/A-0.4930Positive NewsShort Interest ↓Gap DownHigh Trading VolumeCALCCalciMedica3.5274 of 5 stars$2.52-8.7%$16.00+535.2%-42.4%$35.40MN/A-1.6230Earnings ReportShort Interest ↓Analyst RevisionGap UpENLVEnlivex Therapeutics3.346 of 5 stars$1.51+2.7%$10.00+562.3%+42.4%$35.36MN/A-2.2770News CoverageShort Interest ↓Gap UpSNYRSynergy CHC4.0927 of 5 stars$3.84+8.5%$10.00+160.4%N/A$35.29M$34.83M0.0040News CoverageEarnings ReportPLURPluri2.2402 of 5 stars$4.47-7.3%$12.00+168.5%-9.5%$35.18M$330K-0.81150Short Interest ↑STTKShattuck Labs3.6995 of 5 stars$0.73-1.0%$7.50+924.6%-72.4%$35.06M$5.72M-0.53100News CoverageEarnings ReportAnalyst ForecastGap UpXLOXilio Therapeutics2.8061 of 5 stars$0.67+1.5%$3.00+345.8%-14.8%$35.00M$6.34M-0.8070News CoverageEarnings ReportHigh Trading VolumePEPGPepGen3.3451 of 5 stars$1.06-1.4%$7.67+626.7%-84.5%$33.95MN/A-0.3530Gap UpEQEquillium2.8107 of 5 stars$0.94+5.7%$3.00+220.5%+22.7%$33.72M$41.10M-2.4240Earnings ReportShort Interest ↓Gap UpALXOALX Oncology2.9072 of 5 stars$0.61-1.2%$3.30+443.7%-74.6%$33.64MN/A-0.2640Earnings ReportGap DownAKTXAkari Therapeutics3.1123 of 5 stars$1.05-0.5%$5.00+378.5%-69.5%$33.63MN/A0.009Upcoming EarningsGap Up Related Companies and Tools Related Companies CALC Alternatives ENLV Alternatives SNYR Alternatives PLUR Alternatives STTK Alternatives XLO Alternatives PEPG Alternatives EQ Alternatives ALXO Alternatives AKTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:MTNB) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Matinas Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access